See more : Telstra Group Limited (TLGPY) Income Statement Analysis – Financial Results
Complete financial analysis of Cogent Biosciences, Inc. (COGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cogent Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Alliance Growers Corp. (ALGWF) Income Statement Analysis – Financial Results
- BBX Capital, Inc. (BBXIA) Income Statement Analysis – Financial Results
- SaveLend Group AB (publ) (YIELD.ST) Income Statement Analysis – Financial Results
- Trinity Capital Inc. 7.875% Notes due 2029 (TRINZ) Income Statement Analysis – Financial Results
- NEXT plc (NXGPY) Income Statement Analysis – Financial Results
Cogent Biosciences, Inc. (COGT)
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Cost of Revenue | 3.59M | 5.88M | 147.00K | 25.74K | 43.71K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.59M | -5.88M | -147.00K | 7.85M | 22.46M | 9.73M | 8.36M | 6.36M | 2.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.67% | 99.81% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 170.17M | 121.63M | 55.91M | 72.65M | 43.71M | 38.29M | 29.83M | 21.99M | 6.85M |
| General & Administrative | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Other Expenses | 0.00 | 3.61M | 2.81M | -246.00K | 78.00K | 320.00K | 274.00K | 681.00K | 0.00 |
| Operating Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Cost & Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Interest Income | 13.08M | 3.99M | 467.00K | 144.00K | 267.00K | 1.15M | 386.00K | 265.00K | 0.00 |
| Interest Expense | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.27M | 5.88M | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M | 830.00K | 179.00K |
| EBITDA | -205.86M | -134.36M | -75.40M | -34.57M | -30.89M | -34.68M | -24.98M | -18.24M | -6.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,139.52% | -143.02% | -356.32% | -298.82% | -287.02% | -214.77% |
| Operating Income | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M | -19.07M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,044.33% | -143.02% | -369.89% | -312.82% | -300.08% | -220.76% |
| Total Other Income/Expenses | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K | 946.00K | 0.00 |
| Income Before Tax | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -950.43% | -141.49% | -354.76% | -304.93% | -285.19% | -220.76% |
| Income Tax Expense | 0.00 | -7.60M | -467.00K | -8.36M | -1.56M | 1.47M | -386.00K | -265.00K | 0.00 |
| Net Income | -192.41M | -132.64M | -71.81M | -66.45M | -30.27M | -34.53M | -25.49M | -18.12M | -6.59M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -844.25% | -134.55% | -354.76% | -304.93% | -285.19% | -220.76% |
| EPS | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| EPS Diluted | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -2.45 | -0.89 |
| Weighted Avg Shares Out | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 5.86M | 5.86M |
| Weighted Avg Shares Out (Dil) | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 7.40M | 7.40M |
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday,...
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in phase to be presented at CTOS 2022
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
Company to Host Virtual Investor Event on Monday, December 12 Company to Host Virtual Investor Event on Monday, December 12
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR...
Cogent Biosciences: What's Ahead
Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
On-track to present additional data from Phase 2 APEX trial by the end of 2022
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 17,899,698 shares...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,698 shares of...
Source: https://incomestatements.info
Category: Stock Reports